EsoCap’s vision is to improve the lives of patients with serious illnesses through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

EsoCap’s vision is to improve the lives of patients with serious illnesses through the development of a unique topical drug delivery platform for diseases of the upper gastrointestinal tract.

The Scientific Platform

The Scientific Platform

EsoCap AG is a
Swiss privately
funded company
based in Basel.

EsoCap AG is a Swiss privately funded company based in Basel.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short esophageal transit times with less than two seconds from the mouth to the stomach.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short esophageal transit times with less than two seconds from the mouth to the stomach.

EsoCap AG is a Swiss privately funded company based in Basel.

EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

Topical treatment in the upper gastrointestinal tract is extremely difficult to achieve due to ultra-short esophageal transit times with less than two seconds from the mouth to the stomach.

The EsoCap drug delivery platform will represent a CHANGE IN PARADIGM, similar as it happened with aerosol therapy in asthma.

The EsoCap drug delivery platform will represent a CHANGE IN PARADIGM, similar as it happened with aerosol therapy in asthma.

Addressing Major Medical Needs

Application

At the moment there are major limitations in the local treatment of diseases of the upper gastrointestinal tract. Our unique and smart application technology in the upper gastrointestinal tract is broadly applicable with established and novel drug substances. It will be beneficial in at least 6 indications affecting 370 Mio patients.

Collaboration

EsoCap is developing this novel platform together with major partners:

the University of Greifswald in Germany with its institute, the C_DAT (Center of Drug Absorption and Transport), which is a leading European center of excellence operating since 2011.

Addressing Major Medical Needs

Application

At the moment there are major limitations in the local treatment of diseases of the upper gastrointestinal tract. Our unique and smart application technology in the upper gastrointestinal tract is broadly applicable with established and novel drug substances. It will be beneficial in at least 6 indications affecting 370 Mio patients.

Collaboration

EsoCap is developing this novel platform together with major partners:

the University of Greifswald in Germany with its institute, the C_DAT (Center of Drug Absorption and Transport), which is a leading European center of excellence operating since 2011.

Our Approach

Clinical Feasibility

Our approach is to show the clinical feasibility for our unique drug delivery technology in one indication and to seek for a major partner within the biopharmaceutical industry.

First Indication

The first indication will be eosinophilic esophagitis(EoE), a rare inflammatory disease of the esophagus. Current therapeutic options are limited to extremely strict dietary measures, off-label steroid treatment and one product registered only in the EU. These treatment options remain suboptimal for a vast majority of affected patients.

Our Approach

Clinical Feasibility

Our approach is to show the clinical feasibility for our unique drug delivery technology in one indication and to seek for a major partner within the biopharmaceutical industry.

First Indication

The first indication will be eosinophilic esophagitis(EoE), a rare inflammatory disease of the esophagus. Current therapeutic options are limited to extremely strict dietary measures, off-label steroid treatment and one product registered only in the EU. These treatment options remain suboptimal for a vast majority of affected patients.

 EsoCap owns a unique drug delivery platform allowing the topical application of drug substances for the local treatment of diseases of the upper gastrointestinal tract.

Team

EsoCap AG is led by one of the most experienced teams in the industry.

Our team has founded, led and grown some of the most important companies impacting patients’ lives through the development and the commercialization of major life-transforming medicines.

Management

Board Members

Team

EsoCap AG is led by one of the most experienced teams in the industry.

Our team has founded, led and grown some of the most important companies impacting patients’ lives through the development and the commercialization of major life-transforming medicines.

Management

Board Members

News

EsoCap has announced that scientists from the University of Greifswald published exciting data demonstrating that a novel drug delivery technology enables targeted and long-lasting local therapy of the esophagus for the first time (Krause et al., J Control Release 2020; 327:1-7). In contrast to tablets, capsules or viscous fluids, which are known for short esophageal […]

Read more

EsoCap AG announced today that the Japanese Patent and Trademark Office issued a patent under number 6719471 on June 18, 2020, based on international patent PCT/EP2015/002601. The patent is directed at the smart application technology enabling effective topical treatment of several diseases of the esophagus. “Issue of the Japanese patent confirms the novelty of EsoCap’s […]

Read more

EsoCap has announced that Dr Jacques Gonella has been appointed to the Company’s Board of Directors.  “I am delighted to welcome Jacques Gonella to the EsoCap Board,” said Dr Werner Tschollar, Chairman of the Board of EsoCap. ”Jacques will add significant value as an EsoCap Board Member, drawing on 30 years of experience in drug […]

Read more

EsoCap AG announced today that the Russia Patent and Trademark Office issued a patent under number 2714882 on February 20, 2020, based on patent application no. 2017132866/04(057778). The patent is directed at the smart appli­cation technology enabling effective topical treat­ment of several diseases of the esophagus. EsoCap AG is pursuing similar patent applications in other […]

Read more

Contact

EsoCap AG is located in Basel, a major center for innovation.

Contact

EsoCap AG is located in Basel, a major center for innovation.

 2017 © EsoCap AG | Malzgasse 9 | CH-4052 Basel

 2017 © EsoCap AG | Malzgasse 9
CH-4052 Basel

Disclaimer

Read

Welcome to EsoCap AG. By using our website, you are accepting the following:

Copyright and Limitation of Liability

This website and its content are copyrighted by EsoCap AG. You may use, e.g. download or copy any content from this website for personal use only. Any other use of the content of this website is not permitted.

This website is for information purposes only and does not contain medical advice. While we are diligently updating our website, we are not bound by the information published and do not guarantee the content to be accurate or up-to-date. EsoCap AG cannot be held liable for any damage that could arise out of or in connection with the use of this website. EsoCap AG is particularly not responsible for damage resulting from incorrect, incomplete or outdated information or the loss of data. In case we are linking to other websites, EsoCap AG is not responsible for such third-party websites. All such limitations are subject to the extent permissible under the applicable law.

Privacy and Personal Data

Cookie Policy

EsoCap AG respects your privacy. You can browse this website without providing us with personal data. We may collect, store and process your personal data if you contact us by email. We may use your personal data for administrative purposes and to inform you about our services and products. We will not provide third parties with your personal data for purposes other than those listed.

We use cookies on this website. Cookies are small text files which are downloaded onto your hard disk when you access this website. Cookies allow recognizing your preferences or past actions and assist you with navigation on the website.

Disclaimer

Read

Welcome to EsoCap AG. By using our website, you are accepting the following:

Copyright and Limitation of Liability

This website and its content are copyrighted by EsoCap AG. You may use, e.g. download or copy any content from this website for personal use only. Any other use of the content of this website is not permitted.

This website is for information purposes only and does not contain medical advice. While we are diligently updating our website, we are not bound by the information published and do not guarantee the content to be accurate or up-to-date. EsoCap AG cannot be held liable for any damage that could arise out of or in connection with the use of this website. EsoCap AG is particularly not responsible for damage resulting from incorrect, incomplete or outdated information or the loss of data. In case we are linking to other websites, EsoCap AG is not responsible for such third-party websites. All such limitations are subject to the extent permissible under the applicable law.

Privacy and Personal Data

EsoCap AG respects your privacy. You can browse this website without providing us with personal data. We may collect, store and process your personal data if you contact us by email. We may use your personal data for administrative purposes and to inform you about our services and products. We will not provide third parties with your personal data for purposes other than those listed.

We use cookies on this website. Cookies are small text files which are downloaded onto your hard disk when you access this website. Cookies allow recognizing your preferences or past actions and assist you with navigation on the website. You may disable the cookies function in your web browser, if you do not want to allow cookies being stored on your computer. With cookies deactivated, not all features of this website may function properly.

Contact Us

Drop us a line and we'll get back to you.